ImmortaSTEM
Financiado
ImmortaSTEM Transient Immortalisation for Patient Stem Cell Expansion and Thera...
ImmortaSTEM Transient Immortalisation for Patient Stem Cell Expansion and Therapeutic Application
Under an ERC Advanced Grant, and subsequent PoC grant, Professor Shakesheff's team have invented a new intracellular delivery system that overcomes a problem in drug delivery in stem cell culture as well as regenerative medicine a...
Under an ERC Advanced Grant, and subsequent PoC grant, Professor Shakesheff's team have invented a new intracellular delivery system that overcomes a problem in drug delivery in stem cell culture as well as regenerative medicine and other therapeutic approaches. The system, called GAG-binding enhanced transduction (GET), enables intracellular delivery of proteins, nucleic acids and particles into cells that resist other non-viral strategies. The work under ERC Advanced Grant and PoC funding has allowed exemplification of the delivery of proteins that promote pluripotency or differentiation, and delivery and expression of mRNA
This ImmortaSTEM: Proof-of-Concept Application will achieve 7 deliverables that together will generate a robust business plan for commercialisation of a specific application of GET to aid cell therapy attempts. This is a unique approach allowing expansion of a patient’s own cells as a therapy. We will begin by performing a comprehensive market analysis to test our view that GET could be used to expand valuable cells presently defined as challenging or impossible. Next we take account of the market analysis to refine our technical work resulting in a report that provides robust evidence of market required advantages of GET over competitor products for stem cell expansion. This technical work will include a consideration of manufacturing routes and costs of goods. In parallel with the technical work we will commission an independent freedom-to-operate report. Finally, we will initiate confidential discussions with potential partners and customers via face-to-face meetings in Europe and the US.
The final business plan will establish the technical and commercial feasibility of our approaches in one or more of our target markets. We envisage that at the end of the ERC PoC grant we will attract substantial funding to rapidly progress product launches and licenses with significant impact on the regenerative medicine and cell therapy sectors.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2017-06-23
Fecha Fin: 2018-12-31
Fecha Fin: 2018-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2016:
ERC-Proof of Concept-2016
Cerrada
hace 8 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
THE UNIVERSITY OF NOTTINGHAM
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
485.07K€ |
Participante